Late diagnosis of primary hyperaldosteronism in outpatient practice
- Authors: Shcherbina E.S.1, Larina V.N.1
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Pirogov University)
- Issue: Vol 11, No 3 (2025)
- Pages: 124-130
- Section: CLINICAL CASES
- URL: https://journals.eco-vector.com/2412-4036/article/view/687149
- DOI: https://doi.org/10.18565/therapy.2025.3.124-130
- ID: 687149
Cite item
Abstract
Timely diagnosis of resistant arterial hypertension (AH) and, as a consequence, detection of primary hyperaldosteronism (PHA) are remaining to be a serious problem in outpatient practice. This happens due to insufficient awareness of these nosologies among primary care physicians, often incompletely collected anamnesis and insufficient knowledge of modern diagnostic and treatment algorithms. Clinical case described in the article clearly illustrates the consequences of PHA late diagnosis in a young female patient. The absence of a correct diagnosis during 10 years resulted in persistent uncontrolled arterial hypertension and development of target organ damage. This observation highlights the importance of increased vigilance for PHA in patients with treatment-resistant arterial hypertension.
Full Text

About the authors
Ekaterina S. Shcherbina
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Pirogov University)
Email: esscherbina@inbox.ru
ORCID iD: 0000-0001-8619-8123
SPIN-code: 6888-7050
MD, postgraduate student, assistant at the Department of outpatient therapy of the Institute of Clinical Medicine
Russian Federation, 117513, Moscow, 1/6 Ostrovityanova St.Vera N. Larina
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Pirogov University)
Author for correspondence.
Email: larinav@mail.ru
ORCID iD: 0000-0001-7825-5597
SPIN-code: 3674-9620
Dr. Sci. (Medicine), professor, head of the Department of outpatient therapy of the Institute of Clinical Medicine
Russian Federation, 117513, Moscow, 1/6 Ostrovityanova St.References
- Баланова Ю.А., Драпкина О.М., Куценко В.А., Имаева А.Э., Концевая А.В., Максимов С.А. с соавт. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространенности, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023;22(S8):105–120. [Balanova YuA, Drapkina OM, Kutsenko VA, Imaeva AE, Kontsevaya AV, Maksimov SA et al. Hypertension in the Russian population during the COVID-19 pandemic: Sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023;22(S8):105–120 (In Russ.)].EDN: YRUNUX. https://doi.org/10.15829/1728-8800-2023-3785
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–80.PMID: 34450083. PMCID: PMC8446938. https://doi.org/10.1016/S0140-6736(21)01330-1
- Xu Z, Yang J, Hu J, Song Y, He W, Luo T et al.; Chongqing Primary Aldosteronism Study (CONPASS) Group. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol. 2020;75(16):1913–22.PMID: 32327102. https://doi.org/10.1016/j.jacc.2020.02.052
- Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al.; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–2300.PMID: 17161262. https://doi.org/10.1016/j.jacc.2006.07.059
- Клинические рекомендации. Артериальная гипертензия у взрослых. Общероссийская общественная организация «Российское кардиологическое общество», Общероссийская общественная организация «Российское научное медицинское общество терапевтов». Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 62_3. Доступ: https://cr.minzdrav.gov.ru/preview-cr/62_3 (дата обращения – 25.04.2025). [Clinical guidelines. Arterial hypertension in adults. Russian Society of Cardiology, Russian Scientific Medical Society of Internal Medicine. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 62_3. URL: https://cr.minzdrav.gov.ru/preview-cr/62_3 (date of access – 25.04.2025) (In Russ.)].
- Клинические рекомендации. Первичный гиперальдостеронизм. Общероссийская общественная организация «Российская ассоциация эндокринологов». Доступ: https://endoinfo.ru/upload/kr_pga_20.09.2021_4.pdf (дата обращения – 25.04.2025). [Clinical guidelines. Primary hyperaldosteronism. Russian Association of Endocrinology. URL: https://endoinfo.ru/upload/kr_pga_20.09.2021_4.pdf (date of access – 25.04.2025) (In Russ.)].
- Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Völzke H et al. Screening for primary aldosteronism in hypertensive subjects: Results from two German epidemiological studies. Eur J Endocrinol. 2012;167(1):7–15.PMID: 22495491. https://doi.org/10.1530/eje-11-1013
- Chao С-T, Wu V-C, Kuo C-C, Lin Y-H, Chang C-C, Chueh SJ et al. Diagnosis and management of primary aldosteronism: An updated review. Ann Med. 2013;45(4):375–83.PMID: 23701121. https://doi.org/10.3109/07853890.2013.785234
- Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, inflammation, immune system, and hypertension. Am J Hyperten. 2021;34(1):15–27.PMID: 32820797. PMCID: PMC7891246. https://doi.org/10.1093/ajh/hpaa137
- Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to renin ratio as screening tool in primary aldosteronism. Exp Clin Endocrinol Diabetes. 2019;127(2-03):84–92.PMID: 30165708. https://doi.org/10.1055/a-0672-0836
- Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: Mechanistic links. Nat Rev Nephrol. 2019;15(6):367–85.PMID: 31015582. PMCID: PMC7278043. https://doi.org/10.1038/s41581-019-0145-4
- Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50.PMID: 29129575. https://doi.org/10.1016/S2213-8587(17)30319-4
- Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045–50.PMID: 15001583. https://doi.org/10.1210/jc.2003-031337
- Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro M-C et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: A position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020;38(10):1919–28.PMID: 32890264. https://doi.org/10.1097/ HJH.0000000000002510
- Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916.PMID: 26934393. https://doi.org/10.1210/jc.2015-4061
- Young WF Jr. Diagnosis and treatment of primary aldosteronism: Practical clinical perspectives. J Intern Med. 2019;285(2):126–48.PMID: 30255616. https://doi.org/10.1111/joim.12831
- Zhu R, Shagjaa T, Rossitto G, Caroccia B, Seccia TM, Gregori D, Rossi GP. Exclusion tests in unilateral primary aldosteronism (ExcluPA) study. J Clin Endocrinol Metab. 2023;108(2):496–506.PMID: 36373399. https://doi.org/10.1210/clinem/dgac654
- Leung AA, Symonds CJ, Hundemer GL, Ronksley PE, Lorenzetti DL, Pasieka JL et al. Performance of confirmatory tests for diagnosing primary aldosteronism: A systematic review and meta-analysis. Hypertension. 2022;79(8):1835–44.PMID: 35652330. PMCID: PMC9278709. https://doi.org/10.1161/hypertensionaha.122.19377
- Демидова Т.Ю., Титова В.В. Сложности диагностики первичного гиперальдостеронизма. FOCUS Эндокринология. 2023;4(2):59–68. [Demidova TYu, Titova VV. Difficulties in diagnosing primary hyperaldosteronism. FOCUS Endokrinologiya = FOCUS Endocrinology. 2023;4(2):59–68 (In Russ.)].EDN: ZIIQBY. https://doi.org/10.15829/1560-4071-2023-12
- Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C et al.; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689–99.PMID: 28576687. PMCID: PMC5572673. https://doi.org/10.1016/S2213-8587(17)30135-3
- Ладыгина Д.О., Вастистова А.А., Шиленкова Е.С., Платонова Н.М., Бельцевич Д.Г., Фадеев В.В. Первичный гиперальдостеронизм: существующие проблемы и возможные решения. Фарматека. 2024;31(2):8–17. [Ladygina DO, Vastistova AA, Shilenkova ES, Platonova NM, Beltsevich DG, Fadeev VV. Primary hyperaldosteronism: Current problems and possible solutions. Farmateka. 2024;31(2):8–17 (In Russ.)].EDN: XXGVLG. https://dx.doi.org/10.18565/pharmateca.2024.2.8-17
- Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F et al. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study. Hypertension. 2022;79(1):178–86.PMID: 34657442. PMCID: PMC8664996. https://doi.org/10.1161/hypertensionaha.121.18118
- Jaffle G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J et al. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension. 2020;75(3):650–59.PMID: 32008436. https://doi.org/10.1161/hypertensionaha.119.14359
- Zekarias K, Tessier KM. Screening rate for primary aldosteronism among patients with treatment-resistant hypertension: Retrospective analysis of current practice. Endocr Pract. 2022;28(3):271–75.PMID: 34843971. PMCID: PMC8901447. https://doi.org/10.1016/j.eprac.2021.11.085
- Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820–25.PMID: 3661395. https://doi.org/10.1016/0002-9149(87)91030-7
Supplementary files
